Safety of 12-month creatine supplementation combined with resistance training in older adults by Landeryou, Timothy
SAFETY OF 12-MONTH CREATINE SUPPLEMENTATION COMBINED 
 
WITH RESISTANCE TRAINING IN OLDER ADULTS 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements  
For the Degree of Master of Science 
In the College of Kinesiology 
University of Saskatchewan 
Saskatoon 
 
By 
 
TIMOTHY A. LANDERYOU 
 
 
 
Copyright Timothy A. Landeryou, September, 2014. All rights reserved.
       
 
i 
 
 
Permission to Use 
In presenting this thesis in partial fulfillment of the requirements for a Postgraduate 
degree from the University of Saskatchewan, I agree that the Libraries of this University may 
make it freely available for inspection.  I further agree that permission for copying of this thesis 
in any manner, in whole or in part, for scholarly purposes may be granted by the professor or 
professors who supervised my thesis work or, in their absence, by the Head of the Department or 
the Dean of the College in which my thesis work was done.  It is understood that any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed without 
my written permission.  It is also understood that due recognition shall be given to me and to the 
University of Saskatchewan in any scholarly use which may be made of any material in my 
thesis.  
Requests for permission to copy or to make other use of material in this thesis in whole or 
part should be addressed to: 
Dean of the College of Kinesiology 
University of Saskatchewan 
105 Gymnasium Place 
Saskatoon, Saskatchewan 
S7N 5B2 
 
 
 
       
 
ii 
 
ABSTRACT 
 
Introduction: Creatine is a nitrogen-containing compound that is found in many supplements 
that claim to increase muscle mass and there is increasing evidence that creatine supplementation 
can increase muscle mass in older individuals. 
Purpose: To evaluate the safety of 12-months creatine supplementation and resistance exercise 
in older adults by monitoring measures of kidney and liver function, complete blood count, and 
reports of adverse events. 
Methods: Older adults (n=70, males 50 years of age or older (39), and post-menopausal females 
(31)) who were not performing resistance exercise were recruited for the study and randomized 
by computer to creatine (32; 18 males, 14 females) or placebo (38; 21 males, 17 females) groups. 
Other exclusionary criteria were: presence/history or kidney impairments, consumption of 
creatine supplement/bone altering drugs, and the presence of fragility fractures. Participants were 
given creatine or placebo (0.1g/kg/day) consumed before and after resistance training on exercise 
days and with a meal on non-exercise days. The study used a double-blind, placebo-controlled 
design. Blood and urine were collected to assess complete blood cell count, liver function 
indicators (aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), and Bilirubin), and creatinine clearance (kidney function) at baseline, 4 
months, 8 months, and 12 months. A mixed ANOVA was used to determine differences in the 
kidney and liver measures within and between groups, and chi-square analysis was used to 
determine if the frequency counts for liver, kidney, and other adverse events were different 
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between groups. 
Results: There were no significant differences found in either the mixed ANOVA or chi-square 
analysis for liver and kidney function measures. There was a significant difference (p=0.033) 
found between groups in the chi-square analysis for gastrointestinal (GI)/Cramping Adverse 
Events (16 Creatine vs. 6 Placebo). 
Conclusion: The present study indicates that creatine supplementation of 0.1g/kg/day in older 
adults for a 12-month period has no adverse effects on liver or kidney function but can cause 
cramping or GI distress in some individuals.  
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1. INTRODUCTION 
1.1 Creatine 
Creatine is a nitrogen containing compound that is found in high concentrations in type II muscle 
fibers. Approximately 95% of the body’s creatine stores are located in skeletal muscle with the 
remaining 5% found in the brain, liver, kidneys, and testes (Persky & Brazeau, 2001).     
                     
Figure 1-1. Molecular Structure of Creatine 
Creatine is contained in many supplements that claim to increase muscle mass and since its 
introduction in the early 90s, has widely increased in its popularity and use. Sales of creatine 
containing supplements were estimated to be $14 million in the US in 2011 (Eudy, 2013). While 
the supplement is primarily used by young adults and athletes, there is increasing evidence that 
creatine supplementation can increase muscle mass in older individuals. (Brose et al, 2003, 
Candow et al., 2008; Chrusch et al., 2001; Gotshalk et al., 2002 and 2008; Rawson et al., 1999; 
Harris et al., 2011). 
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1.2 Ergogenic Action 
Creatine acts by increasing phosphocreatine (PCr) stores within skeletal muscle (Vandenberghe 
et al., 1997 and 1999). PCr stores are responsible for high-energy, forceful contractions from 
skeletal muscle by allowing quick resynthesis of ATP. They also aid in regeneration of ATP 
stores in “microdomains” which are vital in importance for maintaining cardiac/skeletal muscle 
and brain function (Figure 1.2). These “microdomains”, or cellular compartments, are located in 
the sarcoplasmic reticulum membrane and the myofibrils near the sarcolemma of cardiac and 
skeletal muscle cells and the cellular membrane of brain cells (Guzan et al., 2011). At these sites, 
phosphate is cleaved from PCr by Creatine Kinase and combined with ADP to produce ATP.  
 
Figure 1-2. Illustration of ATP synthesis in microdomains. Adapted from Guzan et al., 2011.   
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1.3 Creatine Metabolism 
While the amount of creatine stored by the body varies greatly, by sex, age, and muscle mass, it 
has been estimated that a 70 kg male will store approximately 120g of total creatine (Brosnan, et 
al., 2011). Stored creatine is either synthesized using the amino acids glycine, methionine, and 
arginine, or absorbed through direct dietary ingestion of creatine. The most abundant sources of 
dietary creatine are animal proteins, specifically red meat and fish (such as salmon and tuna).  
 
Figure 1-3. Creatine Synthesis from Amino Acids. Adapted from Brownan et al., 2011. 
Figure 1-3 (above) outlines the chemical reactions involved in creatine synthesis from amino 
acids. Creatine synthesis requires three enzymes: methionine adenosyltransferase (MAT), 
arginine:glycine amidinotransferase (AGAT), and guanidinoacetate methyltransferase (GAMT) 
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and is an inter-organ process. Guanidino acetic acid (GAA) is synthesized in the kidneys by 
incorporating one molecule of glycine and one amidino group from arginine. It is then 
transported to the liver where a methyl group from methionine is added along with an ATP to 
produce creatine and A-adenosylhomocysteine (Brosnan et al., 2011).  
Once in the blood stream, creatine follows one of two pathways, as outlined in Figure 1-4.  
 
 
 
 
 
 
Figure 1-4. Pathways of Creatine Metabolism Following Oral Ingestion. Adapted from Persky & 
Brazeau, 2001. 
 
The first is conversion to PCr to saturate cells or tissues within the body (as described above) and 
the second is renal elimination. Approximately 90-95% of creatine in the body is stored in 
skeletal muscle as either free (Cr) or phosphorylated (PCr) creatine. Once the body’s storage 
domains are saturated, any remaining creatine is converted to creatinine and is excreted by the 
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kidneys. (Persky & Brazeau, 2001). Creatinine is also produced during skeletal muscule 
contractions as a byproduct of PCr metabolism (Fig. 1-4) to produce ATP and thus creatinine 
levels are largely dependent on individual muscle mass. 
Factors such as age, lean body mass, and amount of ingested creatine have a large impact on 
levels of excreted creatinine. Estimates for the conversion of creatine to creatinine in healthy 
individuals are 1.6-1.7% of the total creatine pool per day (Brosnan et al., 2011) and the normal 
range for 24-hour urine creatinine collection is 500-2000 mg (Creatinine – urine, 2013).  
1.4 Creatine and Aging 
A progressive decline in muscle mass and strength occurs as a result of aging (Rawson & 
Venezia, 2011; Candow & Chilibeck, 2005; Evans, 1995). One possible cause for this decline is 
a reduction in high-energy phosphate metabolism. Most PCr (90-95%) is stored in skeletal 
muscle (Smith et al., 1998) and therefore a loss of skeletal muscle mass with age would arguably 
cause a reduction in PCr (Moller et al., 1980). The positive effects for creatine on increasing 
muscle mass and strength have been well documented by the literature in both animal (Ferreira et 
al, 2005) and young adult populations (Persky & Brazeau, 2001; Rosene et al., 2009) and there is 
increasing evidence for positive effects of creatine supplementation in the aging population as 
well (Brose et al, 2003; Candow et al., 2008; Chrusch et al., 2001; Gotshalk et al., 2002 and 
2008; Rawson et al., 1999, 2002, and 2004; Canete et al., 2006; Harris, 2011). Other studies have 
found no effects of creatine supplementation in older adults (Eijnde et. al, 2003; Bermon et. al, 
1998). A possible explanation for why some studies of older adults supplementing with creatine 
did not find significant results could be the nature of Cr storage. PCr is stored primarily in 
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skeletal muscle and is much more prevalent in Type II vs. Type I muscle fibres. Older adults 
could see an attenuated effect of creatine supplementation on muscle mass and performance for 
two reasons:  Muscle mass decreases with age and there is a shift from Type II to Type I fibres, 
with preferential atrophy of Type II fibres (Deschenes, 2004). This theory is supported by 
research that shows muscle PCr increases significantly more in young adults supplementing with 
creatine versus older adults (Rawson et al., 2002). Other researchers have found that base levels 
of PCr are heavily influential on gains associated with Cr supplementation and in some cases 
older adults can see increases greater than younger adults (REF). Further research of the effects 
of creatine supplementation on older adults is required. 
1.5 Safety & Side Effects 
1.5.1 Animal Studies 
While there is no conclusive evidence of negative side effects of creatine supplementation, there 
have been inconsistent reports that point to the need for caution when using creatine, especially 
within special populations or if using high doses (Kim et al., 2011). Since creatine is synthesized 
in the liver and creatinine is excreted by the kidneys,  creatine supplementation in populations 
who may already have pre-existing conditions which compromise kidney or liver function 
(liver/kidney disease) would be contraindicated. Studies performed on animals supplementing 
with high doses (1-5g/kg/day) of creatine showed increased liver enzyme, urea, and creatinine 
levels in the blood, as well as structural changes to both the liver and kidneys, which indicate 
tissue damage (Souza et al., 2009). Tarnopolsky et al. (2003) showed mice, but not rats, 
developed hepatic inflammatory lesions when supplementing with creatine monohydrate while 
another study found creatine supplementation increased cyst growth and worsened renal function 
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in rats (Edmunds et al., 2001). The authors pointed out differences in metabolism of creatine 
based on species and urged future studies to consider these differences when evaluating the 
physiological and toxicological implications of supplementing with creatine.  
1.5.2 Human Studies 
In humans, two individuals with abnormal kidney function (interstitial nephritis and focal 
glomerular sclerosis) saw improvement upon termination of creatine supplementation (Koshy et 
al., 1999; Pritchard & Kalra, 1998). Both these studies have been refuted by other authors 
(Tarnopolsky, 2010), who attribute the impaired renal function in these individuals to other 
medications (cyclosporine and non-steroidal inflammatory drugs) they were taking at the time.  
While the above cases are serious, they are isolated and many other studies have shown no 
adverse effects of creatine supplementation on the liver or kidneys (Gualano et al., 2008; 
Tarnopolsky, 2010). The absence of liver or kidney dysfunction has also been observed in 
studies supplementing with high doses of creatine (30g/day) and over long periods of time (up to 
5 years) (Poortmans et al., 1997; Poortmans & Francaux, 1999).  
Following those studies, Yu & Deng (2000) showed a metabolic pathway by which creatine is 
converted to methylamine and then formaldehyde. This pathway is outlined in Figure 1-5, found 
on the following page. More recent research (Sale et. al., 2009) also showed increased 
methylamine concentration in individuals supplementing with creatine at a dose of 4 x 5g/day. 
Methylamine, which is deaminated to formaldehyde in this manner, has been linked to vascular 
damage, complications with diabetes, and nephropathy.  
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Figure 1-5. Metabolic Conversion Pathway of Creatine to Formaldehyde. Adapted from Persky 
& Brazeau, 2001. 
Concern about this pathway may be premature however, as a more recent study found no 
difference in formaldehyde excretion between older individuals supplementing with creatine 
versus placebo (Candow et al., 2008). This study did use a low dose of creatine (0.1g/kg), which 
could have prevented the build-up of formaldehyde. Another study showed an increased 
excretion of methylamine and formaldehyde in younger men while supplementing with creatine, 
but that it had no effect on the normal function of the kidneys (Poortmans et al., 2005). Some 
researchers (Sale et al., 2009) have also shown that changing the supplement delivery at a given 
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amount can significantly reduce the formation of methylamine with creatine supplementation. In 
their study, methylamine excretion was significantly reduced at a dosage of 20x1g/day versus 4 x 
5g/day. This would indicate that for most individuals, creatine supplementation can be safe but to 
use caution when working with certain populations with compromised kidney function, or at risk 
of kidney disease, such as older adults. 
Claims of other side effects as a result of creatine supplementation have also been cited. These 
include: gastrointestinal (GI) discomfort, diarrhea/loose stool, dehydration and cramping. GI 
symptoms have been cited in several studies with incidence rates as high as 35% (Juhn, 1999, 
Chrusch, et al., 2001, Groenveld, 2005). Other studies have found low or no incidence of these 
symptoms though, so it remains to be seen whether this is a function of creatine itself or simply 
an improperly administered supplement or dosage. One study which cited a 5% incidence rate 
attributed even this low number to the supplement being improperly self-administered and that 
the symptoms could have been eliminated by taking the supplement with meals and/or better 
mixing it into a viscous medium such as yogurt (Tarnopolsky, 2010). In most cases, GI related 
side effects are also participant reported, and thus will suffer from large variations in reported 
incidence as a result. A more standardized approach to reporting side effects of this nature is 
clearly needed for accurate and meaningful comparisons across studies. 
Other side effects such as muscle cramping and muscle pulls/strains have been reported in the 
literature (Chrusch et al., 2001) as well. These side effects were originally thought to occur due 
to dehydration (Williams & Branch, 1998), which creatine supplementation could cause by 
increasing intracellular water retention (Dalbo et al., 2008). Volek et al. (2001) found that while 
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creatine supplementation increases the aldosterone response, it did not significantly change 
temperature, blood pressure, sweat rate, or sodium/potassium excretion. More recent studies 
have also shown creatine supplementation to have no significant effect on several different 
hydration and thermoregulatory variables (Lopez, 2009), so if creatine supplementation increases 
risk of cramping or muscle pulls/strains, dehydration is not likely the mechanism responsible. 
Another theory that could explain an increased incidence of cramping or muscle pulls/strains 
with creatine supplementation is a higher training volume/intensity. Optimizing creatine stores in 
skeletal muscle could allow participants to push harder in training and cramp as a result. This 
theory is supported by research, which showed increased training volume (kg x reps) in the 
creatine group versus placebo (Chrusch et al. 2001; Wiroth et al., 2001; Candow et al., 2008). 
The reporting of all these side effects has been inconsistent, or anecdotal, and in most cases not 
significant in the literature and thus more evidence is needed to confirm or refute these claims 
(Persky & Brazeau, 2001; Kim et al., 2011). 
1.5.3 Older Adults 
It is evident that the safety and efficacy of creatine use in young, healthy populations is not 
especially controversial, as many studies have been done both in the long and short term with 
minimal and/or anecdotal claims of adverse side effects (Kim et al., 2011). As the therapeutic 
effects of creatine ingestion are further explored, they will continue to be used on other 
populations (such as the elderly) and on a more chronic/long-term basis, thus, the safety of such 
use needs to be evaluated more thoroughly. Several studies have been done to assess possible 
positive effects (Brose et al, 2003; Candow et al., 2008; Chrusch et al., 2001; Gotshalk et al., 
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2002 and 2008; Rawson et al., 1999, 2002, and 2004; Canete et al., 2006; Harris, 2011) of 
creatine in an older population. Various research groups have reported benefits of creatine 
supplementation in older adults, observing everything from increases in aerobic and anaerobic 
exercise performance (Wiroth et al., 2001), functional movement tasks (Canete et al., 2006), and 
body composition (Rawson et al., 2004). Few of these studies took safety and/or side effect 
measurements (Chrusch et al., 2001; Brose et al., 2003), and they were all short in length (<3 
months). Chrusch et al. (2001) found significantly greater incidences of loose stool, muscle 
cramping, and muscle pull/strain in the creatine vs. placebo groups, while Brose et al. (2003) 
found no significant difference in side effects between groups. Neves et al. (2011) also found no 
difference in the glomerular filtration rate (GFR – a measure of kidney function) of post-
menopausal women taking creatine vs. placebo for 12 weeks.  
At present there have been very few studies done to assess the safety of creatine ingestion in 
older adults over a long period of time. Groenveld et al. (2005) found no significant differences 
between creatine and placebo groups for renal function measurements, or incidences of nausea, 
GI discomfort, and diarrhea over a period of 10 months in patients with ALS. Three participants, 
all in the creatine group, had to stop intake of creatine during the course of the study due to 
severe diarrhea (2) and severe nausea (1). Bender et al. (2008) observed markers of renal 
function and reports of GI disturbances in older adults with Parkinson’s Disease taking either 
creatine or placebo over a period of two years. Serum creatinine was significantly different 
between groups at 12 months, but was not significantly different before or after that. This 
indicates possible renal involvement in creatine metabolism, but with no progressive decline in 
kidney health (which likely would have been indicated by steadily higher serum creatinine 
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levels) it does not appear to adversely affect kidney function. Researchers did see significantly 
higher reporting of GI related complaints after 24 months. None of these studies used creatinine 
clearance (widely regarded as the gold standard for kidney function) as an outcome measure, but 
relied on other measures to estimate GFR. 
1.5.4 Kidney Function 
Creatinine clearance (CrCl) is a measure of the amount of creatinine excreted per unit time 
(usually measured in ml/min) and is used to estimate glomerular filtration rate (GFR) thereby 
giving an indication of kidney function. This test requires levels of serum and urine creatinine 
(SCr and UCr) to be measured along with 24-hour urine volume (V) in order to estimate GFR 
using the following equation:    
CrCl = (UCr x V) / SCr 
Creatinine clearance is directly correlated with muscle mass and so it is affected by age, sex, and 
body composition as a result. Females, older adults, and smaller individuals will have lower CrCl 
than males, younger adults, and larger individuals, so CrCl can vary widely by individual. The 
U.S. National Library of Medicine online lists the normal range for CrCl in healthy adults as 97-
137ml/min for males and 88-128ml/min for females (A.D.A.M., 2013). Due to variance in age, 
gender, and laboratory procedures, normal ranges for creatinine clearance will also vary by 
facility. The present study used a normal range of 74-125 ml/min (C.C.P.E., 2013). Creatinine 
clearance levels that exceed the normal range usually indicate an increased ingestion of creatine, 
either from diets high in meat, or supplementation, as creatinine is released into the blood as a 
by-product of creatine metabolism. Elevated creatinine clearance may also be seen during and 
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after exercise, due to muscle damage that occurs which can leak creatine or creatinine into the 
blood (Machado et al., 2012). High creatinine clearance is rarely observed, and is not usually a 
concern, especially in individuals supplementing with creatine, because it indicates an increased 
level of urine creatinine, which simply means that the body is excreting additional creatinine.  
Creatinine clearance below the normal range however, is a concern, because creatinine is 
passively filtered by the kidneys. According to the American Association for Clinical Chemistry 
(A.A.C.C.), any disease or condition that affects the glomeruli can decrease the kidneys' ability 
to clear creatinine and other wastes out of the blood. When this occurs, serum creatinine will be 
increased and creatinine clearance will be decreased because not enough creatinine is being 
filtered out through the kidneys and excreted in the urine (A.A.C.C., 2012). 
A decreased creatinine clearance rate may also occur when there is decreased blood flow to the 
kidneys as may occur with congestive heart failure, a kidney obstruction, or acute or chronic 
kidney failure. The less effective kidney filtration is, the less creatinine can be filtered through 
them and excreted, and the greater the decrease in creatinine clearance will be (A.A.C.C., 2012).  
1.5.5 Liver Function 
Liver function is primarily assessed by measuring the levels of bilirubin and liver enzymes – 
alanine aminotransferase (ALT), alkaline phosphatase (ALP), and aspartate aminotransferase 
(AST), in the blood. Low levels of these substances in the blood are not normally cause for 
concern. Elevated levels can indicate various health concerns depending on which substance is 
elevated, the level of elevation, and the ratio of these substances to each other. 
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Increased ALT in the blood can indicate acute (>10x normal range) or chronic (<4x normal 
range) hepatitis, and mild increases can also be seen in bile duct obstructions, cirrhosis, heart 
damage, alcohol abuse, and hepatic cancer/tumors (A.A.C.C., 2013). 
AST is elevated in similar circumstances to ALT. This includes acute (>10x normal range) and 
chronic (<4x normal range) hepatitis, bile duct obstructions, cirrhosis, and certain liver cancers. 
AST will also be elevated after heart attacks and muscle injury, usually much higher (3-5x) than 
ALT, and will stay elevated for longer than ALT with liver injury. For these reasons, ALT and 
AST are often compared to each other to determine the nature of the illness. (A.A.C.C., 2013). 
Increased ALP levels in the blood will also occur in instances of hepatitis, bile duct obstructions, 
and liver cancer. In hepatitis, ALP is much less elevated than AST and ALT, while if the bile 
ducts are blocked, ALP will be increased (along with bilirubin) much more than AST and ALT. 
Elevated ALP can also indicate increased bone cell activity, which could occur with bone 
diseases such as Paget’s or cancers that have spread to the bone. Moderately increased ALP can 
also be caused by Hodgkin’s lymphoma, congestive heart failure, ulcerative colitis, and certain 
bacterial infections. For these reasons, it is very important that ALP results are compared with 
other markers of liver function to determine whether the cause is liver related or indicative of 
some other disease. An ALP isoenzyme test can also be performed to determine if the high ALP 
is from bone or the liver, if the signs and symptoms or other routine tests are unclear (A.A.C.C, 
2013). 
Elevated bilirubin indicates liver dysfunction, though the nature is dependent on the type of 
bilirubin that is elevated. If unconjugated (indirect) bilirubin is high, it can indicate haemolytic or 
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pernicious anemia, cirrhosis, or a transfusion reaction. If conjugated (direct) bilirubin is high, it 
can indicate viral hepatitis, drug reactions, alcoholic liver disease, bile duct obstructions (due to 
gall stones or scarring), or liver tumors. If conjugated bilirubin levels reach high enough, 
bilirubin may also be present in the urine and is detectable with a dipstick test as part of a 
urinalysis (A.A.C.C., 2012). 
1.6 Purpose 
The present study aims to analyze the long-term safety of creatine use combined with resistance 
training in older adults by studying the effects on the liver, kidneys, and other side effects such 
as muscle cramping and GI discomfort, that are theorized to occur with creatine 
supplementation. This study aims to assess the safety of long-term creatine supplementation 
combined with resistance training within this population by answering the following questions: 
i) Does creatine supplementation combined with resistance training adversely affect 
liver or kidney function in older adults? 
ii) Does creatine supplementation combined with resistance training lead to increased 
incidence of GI symptoms (GI distress, diarrhea, dehydration) and cramping in older 
adults? 
1.7 Hypothesis Statements 
The following hypothesis statements have been created to scientifically answer the questions 
presented in the study purpose: 
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i) Values for liver and kidney function indicators will not differ significantly between 
creatine and placebo groups. 
ii) The number of adverse events related to kidney and liver function will not differ 
significantly between creatine and placebo groups.  
iii) The number of adverse events related to GI symptoms (GI distress, diarrhea, 
dehydration) and cramping associated with creatine supplementation will not differ 
significantly between creatine and placebo groups. 
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2. METHODS 
2.1 Study Design 
The study used a double-blind, placebo-controlled, repeated measures design. Once recruited, 
participants were randomized using a computer-generated allocation schedule, performed by a 
research assistant independent from the rest of the study staff, to one of two groups: (1) 
resistance exercise and creatine supplementation or (2) resistance exercise and maltodextrin 
(placebo). This research assistant also prepared the study kits. Randomization was performed 
using a fixed block size of 4 and a permutated block design with a computer random number 
generator. This means participants were grouped into blocks of 4 and each block received an 
even distribution to creatine and placebo (2 each per block). This method was chosen to keep the 
intervention group sizes close to the same. The allocation sequence was concealed from the 
research assistant enrolling and assessing participants. All researchers who performed 
assessments, supervised training, and performed data entry, were blinded to group assignment. 
Following randomization, there was a familiarization protocol for the resistance training 
exercises. The familiarization period lasted 2 weeks and the purpose was to reduce the amount of 
learning, which might contribute to strength increases in the initial stages of the exercise 
protocol. Following the familiarization period, baseline assessments were performed and 
participants were given their study kits. At 4 month intervals (4, 8, and 12 months) assessments 
were performed again to assess liver and kidney function. Adverse event reporting was 
undertaken throughout the study; participants were encouraged to report adverse events to a staff 
member, as well as proactively collected by staff members who supervised on training days. If 
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warranted, an Adverse Event Form (Appendix A) was completed and filed so that it could be 
included in further analysis. A diagram of the participant flow is seen below (Figure 2-1). 
 
Figure 2-1. Participant Flow Chart 
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2.2 Participants 
Table 2-1 (below) contains demographic data on the participants included in the study.  
Table 2-1. Participant Demographic Data 
Group N  M/F Mean Age Mean Weight Mean Height 
Creatine 32 18/14 58.5 81.6 170.2 
Placebo 38 21/17 57.6 81.2 169.8 
 
Of the 210 individuals recruited for the present study, 140 did not meet inclusion criteria, 36 
declined to participate, and 27 were excluded for other reasons. This left a sample of 70 
individuals who participated. To be eligible for the study, individuals had to be men 50y and 
older, or post-menopausal women (no menstruation for at least 12 months). If women reported 
being post-menopausal for less than two years, menopausal status was verified by determining 
levels of follicle stimulating hormone and leutinizing hormone. Exclusion criteria were: 
-­‐ pre-existing kidney abnormalities -­‐ creatinine clearance values below the normal reference range -­‐ previous fragility fractures -­‐ history of taking medications that affect bone mineral density in the past year, including: 
bisphosphonates, parathyroid hormone, calcitonin, hormone replacement therapy, 
selective estrogen receptor modulators, parathyroid medication, or androgen therapy -­‐ currently taking corticosteroids -­‐ suffer from severe osteoarthritis -­‐ have taken creatine supplementation within the past 6 months 
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-­‐ Crohn’s disease, Cushing’s disease, or severe osteoarthritis -­‐ Currently involved in resistance training (more than 2x20minutes per week) 
Participants were recruited via newspaper advertisements and posters circulated in the city of 
Saskatoon. Table 2-2 (below) indicates medications participants were taking at baseline. 
Table 2-2. Participant Medications at Baseline 
Group 
Participant 
ID Medication 
Creatine 
1 Meloxicam, nasonex 
6 Zocor, Celexa, aspirin 
8 Eltroxin, Citalopram 
32 Baby aspirin 
Placebo 
2 
Calcium, multivitamin, glucosamine, Ginsing, Gingko biloba, 
Ibuprofen 
18 Crestor 
29 Micardis 
46 Fluoxitine, Nu-atenol, amlodipine, altace 
51 Synthroid, nortriptyline, Arthrotec, Aspirin 
61 Wellbutrin 
72 Hydrochlorothiazide, Teva-rabeprazole 
92 Citalopram 
211 Rosuvstatin, Cilazapril monohydrate 
 
2.3 Exercise Protocol 
Before performing the resistance exercise protocol, participants would warm-up on a stationary 
cycle ergometer for 5 minutes and perform light stretching. They would then perform 3 sets of 
10 repetitions to muscular fatigue, with 2-minute rest sessions between sets for each exercise at 
an intensity corresponding to a load equal to or greater than 80% 1-RM (i.e. 80% of their 
maximum strength). Each resistance exercise session took approximately 60 minutes to complete 
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and was performed 3x/week under the supervision of a Certified Exercise Physiologist (CSEP-
CEP) in a controlled environment.  
Participants were encouraged to maintain a regular schedule; working out on the same days each 
week, with a 48-hour rest period between subsequent exercise days to minimize the risk of 
overtraining and fatigue. 
The resistance exercises chosen for the protocol included: hack squat, chest press, lat pull down, 
shoulder press, leg curl/extension, biceps curl, triceps extension, calf press, and back extension. 
These exercises were chosen as they trained all major muscle muscle groups (Candow et al, 2006 
and 2008; Chilibeck et al, 2005). Wrist flexion and extension and ankle plantar 
flexion/dorsiflexion were also used.  
Participants maintained daily training logs where average training volume per session (weight x 
sets x repetitions) was determined and monitored for each participant by a supervisor. Resistance 
was individualized and increased by 1-5kg once the participant could complete 3 sets of 10 
repetitions for that exercise. 
Duration of the exercise protocol was 12 months and compliance with the exercise protocol was 
assessed through the use of logs. 
2.4 Supplementation Protocol 
Creatine monohydrate (RIVALUS Inc.) or placebo was orally administered with half before 
(~5mins) and half after (~5mins) completion of the resistance training protocol on exercise days 
and with meals on non-exercise days. Rationale for timing of supplementation and placebo was 
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that it is more effective for inducing muscle hypertrophy and increasing strength than at a time 
distant from training sessions (Cribb & Hayes, 2006). Both supplements were of the same dosage 
(0.1g/kg/day) and identical in appearance and taste. The placebo was isocaloric to creatine 
monohydrate and contained maltodextrin. Creatine monohydrate and placebo were administered 
in a double-blind fashion in the form of powder mixed with juice or milk. Dosage was chosen as 
it was shown to reduce bone resorption in older males (Candow et al., 2008). There are no “non-
exercise” groups in the study design because creatine has minimal effects without exercise and 
its main ergogenic effect is to increase phosphocreatine stores to allow one to train with a higher 
exercise volume (Chrusch et al., 2001). The intervention duration was 12 months and compliance 
with the supplementation protocol was assessed through the use of logs. Participants were also 
surveyed after the study to assess the effectiveness of our blinding by asking if they thought they 
were on the creatine monohydrate, or the placebo, or were not sure. 
2.5 Measures 
The study relied on three types of measurements to confirm its hypotheses: blood and urine 
markers of liver and kidney function, liver and kidney adverse events, and other adverse events. 
Liver and kidney measurements were taken four times over the course of the study: baseline, 4 
months, 8 months, and 12 months. Adverse events were recorded using adverse event forms 
throughout the study.  
2.5.1 Liver Measurements 
Serum bilirubin and three liver enzyme levels were measured as part of a standard blood panel, 
to assess liver health over the course of the study: alkaline phosphatase (ALP), alanine 
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aminotransferase (ALT), and aspartate aminotransferase (AST). All were measured using in vitro 
tests for their respective quantitative determinations in human serum and plasma on the 
Roche/Hitachi Cobas c501 module, which automatically calculates the analyte concentration of 
each sample. Reliability of testing equipment has been verified in previous research; the 
coefficients of variation (SD / mean) for the test analytes are less than 5% and meet working 
guidelines for analyte testing by the European Working Group, which has more demanding 
standards than the US CLIA (Smolcic et al., 2011). Data sheets containing additional information 
on these substances can be found as Appendix B. Reference ranges and analyte testing methods 
were obtained via information sheets from Cobas. These information sheets can be found as 
Appendix C. 
2.5.2 Alkaline Phosphatase 
ALP was assessed through colorimetric assay in accordance with methods standardized against 
the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) formulation 
(Tietz et al., 1983). In the presence of magnesium and zinc ions, p-nitrophenyl phosphate is 
cleaved by phosphatases into phosphate and p-nitrophenol. The p-nitrophenol released is directly 
proportional to the catalytic ALP activity and is determined by measuring the increase in 
absorbance. 
2.5.3 Alanine Aminotransferase 
ALT was assessed by assay, which follows the recommendations of the IFCC, but was optimized 
for performance and stability (Bergmeyer et al., 1985; ECCLS, 1989). ALT catalyzes the 
reaction between L-alanine and 2-oxoglutarate. NADH reduces the pyruvate formed in a reaction 
catalyzed by lactate dehydrogenase to form L-lactate and NAD+.  
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2.5.4 Aspartate Aminotransferase 
AST was assessed by assay that follows the recommendations of the IFCC, but was optimized 
for performance and stability (Bergmeyer et al., 1985, ECCLS, 1989). AST catalyzes the transfer 
of an amino group between L-aspartate and 2-oxoglutarate to form oxaloacetate and L-
glutamate. The oxaloacetate then reacts with NADH in the presence of malate dehydrogenase to 
form NAD+. The rate of NADH oxidation is directly proportional to the catalytic AST activity. It 
is determined by measuring the decrease in absorbance.  
2.5.5 Bilirubin 
Bilirubin was assessed using the Diazo method (Wahlefeld et al., 1972). Total bilirubin, in the 
presence of a suitable solubilizing agent, is coupled with a diazonium ion in a strongly acidic 
medium (pH 1-2). The intensity of the colour of the asobilirubin produced is proportional to the 
total bilirubin concentration and is measured photometrically.  
2.5.6 Kidney Measurements 
Kidney function was assessed through measurements of creatinine in the blood as well as in the 
urine. Data sheets containing additional information on these analytes can be found as Appendix 
D. Both were measured using in vitro tests for their respective quantitative determinations in 
human serum, plasma, and urine on Roche/Hitachi cobas c systems, which automatically 
calculate the analyte concentration of each sample. Reference ranges and analyte testing methods 
were obtained via information sheets from cobas. These information sheets can be found as 
Appendix E. Serum and urine creatinine was determined through an enzymatic method based on 
the conversion of creatinine with the aid of creatininase, creatinase, and sarcosine oxidase to 
glycine, formaldehyde, and hydrogen peroxide. Catalyzed by peroxidase, the liberated hydrogen 
       
 
25 
 
peroxide reacts with the 4-aminophenazone and HTIB to form a quinone imine chromagen. The 
colour intensity of the quinone imine chromagen formed is directly proportional to the creatinine 
concentration in the reaction mixture.  
2.5.7 Creatinine Clearance 
Using both serum and urine creatinine measurements (from 24-hour urine collection) allows us 
to assess creatinine clearance (CrCl), which much more accurately reflects GFR and kidney 
function. CrCl is expressed as the amount of creatinine excreted per unit time (usually ml/min) 
and is determined using the following equation: 
Creatinine Clearance = (Urine Creatinine/Serum Creatinine) x (Urine volume/time) 
2.5.8 Liver and Kidney Adverse Events 
The tests listed above were grouped for each organ (kidney or liver) and any individual test result 
that was outside the normal range was flagged as an adverse event. Participants who tested 
outside the reference range(s) for any measures at baseline were flagged and subsequent test 
results outside the reference range(s) were not counted unless they had returned to normal first. 
An adverse event for the same measure was also not counted twice if it occurred on subsequent 
tests. For example, if Participant #27 had an adverse event for AST at baseline and at 4 months, 
this would not be counted as an adverse event. If AST was elevated at baseline, returned to 
normal at 4 months, and was high again at 8 months this would be counted as an adverse event. 
If AST remained high at 12 months, it would still only be counted as one adverse event. Adverse 
events for different measures that occurred at the same time point e.g.) AST and ALT elevated at 
4 months, were counted as separate adverse events. Lastly, values outside the normal range that 
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would not indicate a health problem, such as low liver enzyme levels, were not included as 
adverse events. Moderate elevations in blood and urine creatinine were also not included because 
these would be expected to increase during creatine supplementation due to the breakdown of 
creatine to creatinine. A kidney problem would be indicated by low creatinine clearance, where 
there is a buildup up of creatinine in the blood due to inadequate clearance by the kidneys, so 
blood creatinine is high relative to urine creatinine levels. Adverse event totals were compared 
between groups to give additional information on our collected data. Different conclusions 
would likely be drawn if many participants saw a moderate rise in observed measures as opposed 
to a few participants with extreme rises, even though this might have the same effect on the 
mean.  
2.5.9 Other Adverse Events 
Research assistants made inquiries about adverse events each time they had contact with 
participants. An adverse event form was used for causality assessment of the intervention (not 
related, unlikely, possibly, probably, definite), whether the adverse event was “serious” (i.e. 
resulted in death, life-threatening, required hospitalization, or resulted in persistent disability) or 
“non-serious”, and its intensity (mild, moderate, severe, life-threatening). The definitions for 
these are below, and follow ICH guidelines (ICH, 1994). Relationship to the intervention was 
determined by exploration of alternate causes and dechallenge/rechallenge of the 
supplement/exercise protocol used in previous research. AEs reported by participants initially 
recorded as “Not Related” or “Unlikely” depending on whether an alternative explanation could 
be established. If a temporal relationship but alternative explanation both existed, the AE was 
classified as “Possible” and tested using a dechallenge/rechallenge protocol. Dechallenge 
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involves removing the intervention (supplement/exercise) for a period of 1-2 weeks and 
monitoring the symptom(s). If the symptom(s) subside or disappear then dechallenge is 
confirmed and the relationship status is reclassified as “probable”. Rechallenge involves 
reintroducing the intervention once the symptom(s) have subsided. If they return upon 
reintroduction, then rechallenge is confirmed and the relationship status is reclassified as 
“definite”. Table 2-3 (below) provides a description of each relationship: 
Table 2-3. Relationship of Adverse Events to Intervention 
Relationship Description/Determination 
Not Related AE is not related to intervention 
No temporal/suggestive relationship; alternative causal relationship established 
Unlikely AE is unlikely related to intervention 
Temporal relationship exists but alternative explanation more likely 
Possible 
AE may be related to intervention 
Temporal relationship suggestive; could not be confirmed by 
challenge/dechallenge 
Probable AE is likely related to the intervention 
Confirmed by dechallenge 
Definite 
AE is definitely related to the invervention/has no alternate reasonable 
explanation 
Confirmed by dechallenge and rechallenge 
 
The participant using the following definitions rated intensity of adverse events: 
Mild: Awareness of sign or symptom, but easily tolerated 
 
Moderate: Discomfort enough to cause interference with normal daily activities 
 
Severe: Inability to perform normal daily activities 
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Life Threatening: Immediate risk of death from the reaction as it occurred 
 
Adverse events that have been associated with creatine supplementation in previous research (GI 
discomfort, cramping, etc.) were grouped together and tabulated over the course of the study as 
previous research had indicated a possible relationship between creatine supplementation and 
some of these side effects in older individuals (Chrusch et al., 2001). These adverse events were 
compared across groups once the study was complete to assess a possible relationship.  
2.6 Statistical Analysis 
A group x time (2x4) mixed ANOVA was used to determine differences both between and 
within groups for all liver and kidney measurements over the course of the study. Significant 
main effects were tested post hoc using the Pairwise method and Bonferroni adjustment to 
determine which means were significantly different. Where sphericity violations occured, 
Greenhouse-Geisser correction was used. Missing data points were replaced using the last 
observation carried forward (LOCF) to retain participant numbers vs. listwise deletion, which is 
the default for SPSS. This method is commonly used in pharmaceutical and longitudinal 
research. Group mean was substituted in instances where last observation was not available. All 
ANOVAs and post hoc tests were performed using SPSS 20. 
Chi-square analysis was performed to determine any significant difference between the number 
of adverse events for liver measurements, kidney measurements, and GI/cramping related 
adverse events between groups over the course of the study. Chi-square analysis performed using 
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online tool via quantpsy.org (Preacher, 2001). Statistical significance was set at α=0.05. Data are 
expressed as mean (SD) unless otherwise indicated. 
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3. RESULTS 
3.1 Liver Measures 
3.1.1 Aspartate Aminotransferase (AST)  
Mauchly’s Test of Sphericity was significant W(5) = 0.620, p<.05, therefore sphericity cannot be 
assumed. Analysis of variance revealed a significant main effect of time on AST across group. 
F(1.914,130.141) = 9.550, p < 0.001, ηp2 = 0.123 but no significant main effect of group on AST 
across time. F(1,68) = 2.410, p = 0.125, ηp2 = 0.034 and no significant interaction of time and 
group. F(1,68) = 0.448,  p = 0.505, ηp2 = 0.007.  
 
Figure 3-1. Graph of AST 
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AST levels in both groups decreased significantly over the course of the study. Post hoc revealed 
that AST levels decreased significantly between baseline and 4 months (p=0.003), remained 
significantly lower than baseline at 8 months (p=0.001) and 12 months (p=0.016).  
The effect size (ηp2 = 0.034) was quite small between the two groups and there was no 
significant interaction. Mean AST for both groups also remained within the normal range (10-
34IU/L) for the duration of the study. 
3.1.2 Alanine Aminotransferase (ALT) 
Mauchly’s Test of Sphericity was significant W(5) = 0.556, p<.05, therefore sphericity cannot be 
assumed. There was a significant main effect of time on ALT. F(2.222,151.065) = 8.506,  p < 
0.001., ηp2 = 0.111 across group but no main effect of group on ALT pooled across time F(1,68) 
= 2.645, p = 0.109, ηp2 = 0.037. There was also no significant interaction of time and group, 
F(1,68) = 2.643, p = 0.109, ηp2 = 0.037. 
 
ALT values for both groups decreased from baseline to 4 months. While this difference only 
approached significance p = 0.052, it became significant at 8 months p = 0.003 and remained 
significantly lower at 12 months p = 0.002. The effect size was small ηp2 = 0.183, there was no 
significant interaction, and both were still within the normal range (10-40IU/L). 
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Figure 3-2. Graph of ALT 
 
3.1.3 Alkaline Phosphatase (ALP) 
 Mauchly’s Test of Sphericity was significant W(5) = 0.496, p<.05, therefore sphericity cannot 
be assumed. There was a significant main effect of time F(2.164,147.153) = 10.017, p < 0.001, 
ηp
2 = 0.128 on ALP, but no main effect of group F(1,68) = 0.059, p = 0.809,  ηp2 = 0.001 and no 
significant interaction of time and group F(2.164,147.153) = 1.652,  p = 0.179, ηp2 = 0.024.  
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Figure 3-3. Graph of ALP 
 
ALP increased significantly in both groups over the course of the study. Post hoc revealed that 
ALP increased significantly between baseline and 4 months p = 0.002 and remained significantly 
higher than baseline at 8 and 12 months p < 0.001. The effect size for this difference was 
relatively small, ηp2 = 0.128, and both groups’ ALP levels also remained well within the normal 
range (35-130IU/L) at all time points. 
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3.1.4 Bilirubin 
 Mauchly’s Test of Sphericity was significant W(5) = 0.803, p<.05, therefore sphericity cannot 
be assumed. There was a significant main effect of time on Bilirubin across groups. 
F(2.635,179.187) = 27.097, p < 0.001, ηp2 = 0.285. There was not a significant main effect of 
group on Bilirubin pooled across time. F(1,68) = 0.000, p = 0.983, ηp2 = 0.000 or a significant 
interaction of time and group. F(2.635,179.187) = 1.016,  p = 0.380, ηp2 = 0.015.  
 
Figure 3-4. Graph of Bilirubin 
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largest of all tested variables, but was still relatively small ηp2 = 0.285, and bilirubin levels in 
both groups at all timepoints remained within the normal range (up to 21 umol/L). 
3.1.5 Liver Adverse Events - Chi-Square Analysis 
Chi-square analysis of liver adverse events revealed no significant difference in adverse events 
reported by group χ2(1, N=11) = 0.091, p=0.763 and the difference remained statistically not 
significant when Yates’ corrected χ2(1, N=11) = 0.000, p=1.000.  
Table 3-1. Liver Adverse Events 
 
Group 
Total 
AEs Timepoint (# AEs) Type (#) 
Creatine 5 
4 months (2) High AST, High ALT 
8 months (1) High Bilirubin 
12 months (2) High AST, High ALT 
Placebo 6 
4 months (1) High Bilirubin 
8 months (3) High AST, High ALT, High ALP 
12 months (2) High AST, High Bilirubin 
 
 
3.2 Kidney Measures 
3.2.1 Serum Creatinine 
Mauchly’s Test of Sphericity was significant W(5) = 0.777, p<.05, therefore sphericity cannot be 
assumed. There was a significant main effect of time F(2.588,175.955) = 2.887, p = 0.045, ηp2 = 
0.041 across group, but there was no significant effect of  group across time F(1,68) = 1.378, p = 
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0.245, ηp2 = 0.020  on serum creatinine. There was also no significant interaction of time and 
group F(2.588,175.955) = 2.267,  p = 0.092, ηp2 = 0.032.  
 
 
 Figure 3-5. Graph of Serum Creatinine 
 
Both groups saw a significant decrease in serum creatinine over the course of the study. Post hoc 
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3.2.2 Urine Creatinine 
There was no significant main effect of time F(3,204) = 2.093, p = 0.102, ηp2 = 0.030 or group 
F(1,68) = 1.782, p = 0.186, ηp2 = 0.026 on urine creatinine. There was also no significant 
interaction of time and group. F(3,204) = 1.976,  p = 0.119, ηp2 = 0.028.  
 
Figure 3-6. Graph of Urine Creatinine 
 
Urine creatinine, while not significantly different between groups, did appear to indicate a trend 
towards being different, with p levels being between 0.1 and 0.2 for both main effects and the 
interaction. Using a more liberal α, a significant difference could have been seen, even though 
the effect sizes were very small, and values for both groups stayed within the normal range (7.5-
16mmol/L) throughout the study.  
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3.2.3 Creatinine Clearance 
Mauchly’s Test of Sphericity was significant W(5) = 0.802, p<.05, therefore sphericity cannot be 
assumed. There was a significant main effect of time F(2.597,176.601) = 4.221, p = 0.009, ηp2 = 
0.058, but no main effect of group F(1,68) = 0.588, p = 0.446, ηp2 = 0.009 on creatinine 
clearance. There was also no significant interaction of time and group. F(2.597,176.601) = 1.120, 
p = 0.338, ηp2 = 0.016. 
 
Figure 3 – 7. Graph of Creatinine Clearance 
There was a significant increase in the creatinine clearance of both groups during the study. Post 
hoc revealed a significant increase in creatinine clearance from baseline to 4 months p = 0.003, 
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but this difference became not significant at 8 months p = 0.166 and remained not significant at 
12 months p = 0.091. The effect size was very small ηp2 = 0.058, and the means for both groups 
at all time points remained within the normal range for healthy adults (93-133ml/min). 
3.2.4 Kidney Adverse Events - Chi Square Analysis 
There was only 1  adverse event related to kidney function found in either group: creatine = 0, 
placebo = 1 (low creatinine clearance). Chi-square analysis was not performed due to the 
extremely low number of adverse events (one total) over the course of the study.  
3.3 Other Adverse Events 
3.3.1 Chi-Square Analysis 
Chi-square analysis of reported adverse events that have been thought to be linked to creatine 
supplementation (GI distress, cramping, etc.) revealed a significant difference in adverse events 
reported by group χ2(1, N=22) = 4.55, p=0.033 although the difference was not significant when 
Yates corrected: χ2(1, N=22) = 3.68, p=0.055. This suggests that there could be a link between 
creatine supplementation and these types of side effects that have occurred in other studies 
previously. The frequency and type of each adverse event is listed in Table 3-2 on the next page: 
3.3.2 Summary/Conclusions  
There was a significant difference between the total number of other AEs in the creatine vs. 
placebo groups, which indicates creatine supplementation may contribute to side effects such as 
diarrhea and muscle cramps.  
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Table 3-2. Other Adverse Events 
Group 
Total 
AEs Type (#) Intensity (#) Related (#) 
Creatine 16 Indigestion (1), Heartburn (1) Mild (2) Possible (2) 
    Nausea (1) Mild Possible 
    Stomach Pain (1), Cramps (1) Mild (2) Possible, Probable 
    Constipation (1) Mild Possible 
    Diarrhea (5) Mild (5) Probable (1), Possible (4) 
    Muscle Cramping (5) Mild (4), Moderate (1) Possible 
Placebo 6 Indigestion Mild Possible 
    Nausea (2) Mild (2) Unlikely (1), Definite (1) 
    Bloating  Mild Possible 
    Muscle Cramping (2) Mild (2) Possible (2) 
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4. DISCUSSION 
4.1 Summary of Important Results 
Results of the present study showed significant changes in all measures over time except for 
urine creatinine, although none of these showed significant differences between groups nor did 
any show an interaction between time and group. AST and Bilirubin significantly decreased from 
baseline to 4 months and remained significantly lower than baseline at 8 and 12 months. ALT 
decreased between baseline and 4 months, but this difference was not significant until 8 and 12 
months, while SCr was not significantly lower than baseline until 12 months. ALP significantly 
increased from baseline to 4 months and remained significantly higher than baseline at 8 and 12 
months while CrCl significantly increased from baseline to 4 months but the difference was not 
significant at 8 and 12 months.. AST, ALT, and UCr all showed trends towards a main effect of 
group (p = 0.125, 0.109, and 0.186) but these were not significant.. The differences found 
between the frequency counts of Adverse Events (AEs) related to liver function and kidney 
function between groups were also not significant. Importantly, we did discover a significant 
difference in the frequency counts for GI and muscular cramping related AEs between groups 
(creatine: 16 events; placebo: 6 events; p<0.05).  The creatine group reported indigestion (n=1), 
heartburn (n=1), nausea (n=1), stomach pain/cramps (n=2), constipation (n=1), diarrhea (n=5), 
and muscle cramping (n=5); whereas the placebo group reported indigestion (n=1), bloating 
(n=1), nausea (n=2), and muscle cramping (n=2). Most of these AEs were rated as “mild” in 
intensity; one muscle cramping AE in the placebo group was rated as “moderate”.  
An unexpected finding was that SCr and three liver measures (AST, ALT, and Bilirubin) 
dropped in both groups over the course of the study. This was unexpected, as previous literature 
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has shown acute increases in liver enzyme levels with resistance exercise (Nathwani et al., 2005; 
Tarnopolsky, 2010). The fact that some of these decreases were statistically significant, but did 
not have a group x time interaction, could indicate possible positive effects of resistance exercise 
on liver health in the long-term. This theory is supported by results from Souza et al. (2005), who 
found increased liver enzymes (AST and ALT) in sedentary rats but not exercised rats 
supplementing with creatine. Excitement may be premature though, as all levels still remained 
within normal ranges, and drastic changes in liver enzyme levels are usually required to indicate 
decline in liver health, not to mention moderate variations in liver enzymes are not often accurate 
indicators of liver function. 
These results indicate that creatine supplementation of 0.1g/kg/day in older adults over 12 
months may not adversely affect liver or kidney health, although strong conclusion statements 
are difficult to draw due to the study’s lack of power. The results also indicate creatine 
supplementation of this duration and dosage can significantly increase mild to moderate side 
effects related to GI symptoms and muscle cramping. 
4.2 Results versus Hypotheses 
The results of this study support the hypothesis that creatine supplementation of 0.1g/kg/day 
dosage in an older population over a twelve month period will not significantly increase markers 
of liver or kidney dysfunction (Figures 3-1 to 3-7, Table 3-1), although the protocol used can 
significantly increase ALP and CrCl. The hypothesis that the frequency of adverse events related 
to liver and kidney function reported would not be significantly different was also supported by 
our results. These findings add credibility to the claim that creatine supplementation may be safe 
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within this population over the long term, but additional, more powerful studies are needed to 
strengthen this assessment. 
Our results did find a significant difference in the frequency of adverse events related to GI 
symptoms and muscle cramping reported (Table 3-2), thus forcing us to conclude that creatine 
supplementation at this dose and in this population can contribute to an increased incidence of 
these side effects. 
4.3 Study Strengths  
This is the only study to measure the effects of creatine supplementation and resistance exercise 
on kidney and liver function in an older population over a twelve-month period. There have been 
studies done on older adults (Neves et al., 2011; Candow et al., 2008; Chrusch et al., 2001) and 
in the long-term (Poortmans et al., 1999; Schroder et al., 2005), but very few that have studied 
older adults over the long term (Groeneveld et al., 2005; Bender et al., 2008). Both of these 
studies observed specific older populations (adults with ALS and Parkinson’s Disease 
respectively) and did not incorporate resistance training, which has been shown to influence 
some of the hepatic and renal outcome measures associated with creatine supplementation in rats 
(Souza et al., 2009). Many researchers (Kim et al., 2011; Juhn & Tarnopolsky, 1998) have 
observed the need for long term, randomized, placebo-controlled studies in the literature to more 
accurately assess the effects of creatine supplementation in this population and time period. The 
current study adds to this lacking, but slowly growing research area.  
4.3.1 Creatinine Clearance 
Measurements of serum creatinine can be used in predictive equations to determine GFR and 
thereby ascertain kidney function. This method is very accurate, but contraindicated in 
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individuals supplementing with creatine due to the nature of creatine metabolism, which is 
spontaneously converted to creatinine following ingestion (National Kidney Foundation), thus 
inflating this measure in the absence of renal dysfunction. Creatinine clearance (CrCl), 
determined by 24-hour urine collection and serum levels of creatinine, is a valuable alternative, 
and may provide better estimates of GFR than predictive equations and serum creatinine in 
individuals supplementing with creatine (National Kidney Foundation).  Other researchers 
(Gualano et al., 2008) have noted difficulty in using CrCl as 24 hour urine collection is required 
and participant compliance for this measure can be unreliable. The length of the current study 
made compliance less onerous as participants were only required to perform this measure four 
times, with each collection spread over several months.   
Even though the differences were not statistically significant, the creatine group’s urine 
creatinine and creatinine clearance levels increased by 3.4% and 7.6% over the course of the 
study (vs. -1.5% and 2.2% respectively in the placebo group). This seems to indicate that the 
supplement was being metabolized, perhaps just not in large enough quantities to have a 
significant effect on these measures. It is suggested that creatinine excretion is proportional to 
muscle mass (Tarnopolsky, 2010) and thus decreases with age. This indicates urine creatinine 
levels, and therefore creatinine clearance, would likely be lower in an older population and may 
not have been affected by creatine supplementation in this study as much as those observed in 
studies involving younger populations. Some other researchers, however, found no difference in 
urine creatinine levels between old and young participants supplementing with creatine (Rawson 
et al., 2002), although the duration of that study was only one week. 
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4.3.2 Liver Measures 
The number of measures taken indicative of liver health is also a strength of the current study. 
Previous research has indicated that ALT and AST levels may not be accurate representations of 
hepatic function in an environment with elevated creatine kinase activity because both of these 
enzymes exist in high levels within skeletal muscle (Tarnopolsky et al., 2010). The present study 
also measured serum Bilirubin and ALP levels in an effort to strengthen any changes that might 
be seen in liver enzyme activity as a result of long-term creatine supplementation. Procedures for 
procuring and testing samples were also well established and controlled by medically trained 
personnel, because these serum measurements are also part of a standard medical blood panel.  
4.4 Study Limitations 
The number of participants in the current study may have limited the analysis. Urine creatinine 
and creatinine clearance both increased to a greater extent in the creatine group vs. the placebo 
group but these increases were not significant. Sample size calculations showed a much larger 
participant pool would have been needed for this difference to be significant (161 and 229 per 
group respectively). Calculations to determine main effect differences for group showed that 
300-400 participants would have been required to see significant differences between groups for 
AST, ALT, SCr, UCr, and CrCl. Related to participant number is retention of participants. 210 
individuals were initially recruited for the study and only 70 participants met inclusion criteria 
and were randomized. Over the course of the study several dropped out, and 20 missed at least 
one measurement of the 4 that were taken. The LOCF method to substitute missing data points 
was implemented, so that pairwise deletion was avoided and sample size could be preserved. 
This method is commonly used in pharmaceutical and longitudinal research but obviously it 
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would have been better to have the actual measurements from participants. Another limitation 
related to statistical analysis was the intent to treat analysis method. A stricter per protocol 
analysis would have been more sensitive to change in participant groups and may have allowed 
significant differences to be seen. 
It has also been shown that muscle PCr concentrations are influenced to a greater degree by 
creatine supplementation in younger populations, versus older, (Rawson, et al., 2002). While this 
is mostly attributed to differences in muscle mass, it’s possible that an absorption/metabolism 
issue could also be at work. Both these factors could contributed to the effects of creatine 
supplementation in the present study being attenuated by the age of the participants. While this 
was unavoidable given that we were investigating this population specifically, it should be noted 
due to its likely effects on the outcome measures. 
4.5 Previous Literature 
Direct comparisons are difficult given that this was one of the only studies to use creatinine 
clearance as a measure of kidney function; most other studies used serum creatinine, sometimes 
combined with predictive equations to estimate GFR. Our results were consistent with research 
showing no adverse effects of creatine supplementation on renal function (Gualano et al., 2008; 
Groeneveld et al., 2005; Poortmans et al.,1999) and liver enzyme activity (Tarnopolsky et al., 
2008; Kreider et al., 2003) and was in contradiction of literature which showed adverse effects of 
creatine on these systems (Keys et al., 2001; Duarte et al., 1999; Yu&Deng 2000; Pritchard & 
Kalra 1998).  
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4.5.1 Creatine and Liver Function 
The effects of creatine supplementation on liver function have been fairly consistent. Aside from 
one study which showed elevated liver transaminases in football players supplementing with 
creatine (Kreider et al., 1998) and another which showed liver inflammation in mice given 
creatine monohydrate (Tarnopolsky, 2003), evidence supporting the claim that creatine 
supplementation may damage the liver is extremely sparse. The reason postulated that some 
research has found evidence that creatine supplementation has adverse effects on liver function is 
a reliance on measures of AST and ALT, which have been shown in the literature to become 
elevated under conditions of skeletal muscle damage consistent with resistance training 
(Saengsirisuwan et al., 1998; De Paz et al., 1995; and Fallon et al., 1999). These results are 
supported by another study that showed elevated AST and ALT levels in patients with muscular 
necrosis (Nathwani et al., 2005). It has been suggested that serum AST and ALT levels may not 
be reliable indicators of liver function in situations where creatine kinase levels are elevated, for 
example during resistance exercise, caffeine supplementation, etc (Tarnopolsky, 2010). Studies 
supporting the theory that creatine supplementation has no adverse effects on liver function, used 
γ-glutamyltransferase and bilirubin to measure liver stress and found no significant increases in 
groups supplementing with creatine (Tarnopolsky et al., 2008, Kreider et al., 2003). Conclusions 
drawn from these studies are extremely valuable when reviewing our data, because the majority 
of liver related AEs in both groups were AST and ALT (4/5 in the creatine group and 3/6 in the 
placebo group). The conclusion that liver function is not affected by creatine supplementation is 
strengthened by the ANOVA data, which showed three of the four liver measures (AST, ALT, 
and Bilirubin) significantly decreased during the study. Increased levels of AST are associated 
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with liver damage/disease. Increased Bilirubin levels are also associated with liver stress, so 
while a decrease during the study cannot be definitively labelled a health benefit, it would seem 
to indicate no negative effects, especially considering the levels of both groups still remained 
within the normal range for healthy adults (up to 21 umol/L).  
It is possible the exercise intervention was responsible for this decrease in the form of a training 
adaptation, as neither supplement is known to cause decreased AST, ALT, or Bilirubin on its 
own, but some research has shown increased ALT and AST in sedentary rats vs. exercised rats 
both supplementing with creatine (Souza et al., 2009). The increase in ALP seen is also likely 
due to bone activity rather than an indication of liver stress because of what was seen in the other 
liver measures, but this should be explored in future research. ALP levels in both groups and at 
all time points were well within the normal range of 35-130 IU/L. The ANOVA data also 
showed no group x time interactions, indicating that even the significant changes in some 
variables occurred in the same way for both groups so it’s more likely they occurred due to the 
exercise intervention, which both groups performed, as opposed to the different supplement 
taken. The lack of evidence in the literature, combined with the present research, makes it seem 
likely that creatine supplementation does not adversely affect liver function, but because of the 
liver’s role in creatine metabolism it is prudent to observe liver function in individuals 
supplementing with creatine, especially those in populations at risk of liver complications such 
as older adults.  
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4.5.2 Creatine and Kidney Function 
The kidneys’ role in creatine metabolism is well known, and the possible adverse effects of 
creatine supplementation on kidney function gained mainstream attention following the 
publication of two studies which showed improvement of kidney function in two individuals 
with kidney disease following the termination of creatine supplementation (Pritchard & Kalra, 
1998; Koshy et al., 1999). Research has also shown increased cyst growth and a decline in renal 
function of rats supplementing with creatine (Edmunds et al., 2001). Since then, many studies 
have been done which indicate no harmful renal effects of creatine supplementation in humans 
(Poortmans & Francaux, 1999; Gualano et al., 2008; Tarnopolsky, 2010). So while much of the 
more current research finds no adverse effects of creatine supplementation on renal function, the 
total body of research on the subject remains mixed.  
The current study measured serum creatinine (SCr), urine creatinine (UCr), and creatinine 
clearance (CrCl) to thoroughly assess kidney function over the course of twelve months. Both 
groups saw a significant decrease in SCr between baseline and 12 months, which would seem to 
indicate that they were not able to maintain their creatine stores over time. This is surprising, 
because creatinine is a byproduct of creatine metabolism, and so a group supplementing with 
creatine would be expected to have a higher level of serum creatinine than a placebo group, not 
to mention we would have thought the creatine group would maintain their creatine levels due to 
the supplement protocol. While the decrease was significant, the means for both groups remained 
within the normal range for healthy adults (45-110 umol/L) over the course of the study.  
Levels of urine creatinine behaved slightly differently between groups, with the creatine group’s 
level slightly increasing and the placebo group’s level slightly decreasing over the course of the 
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study. This difference was not significant, likely due to the high amount of variance seen in the 
measurement data. A difference would make sense between groups because excess creatinine is 
excreted in the urine, thus creatine supplementation would likely cause an increase in urine 
creatinine levels. Because none of the differences were significant and the means for both groups 
remained within the normal range for healthy adults of 7.5 – 16 mmol/L (Junge et al., 2004) at 
nearly all time points, the evidence suggests that creatine supplementation does not have a 
significant effect on urine creatinine levels at the tested dosage. It is possible that a significant 
effect could be seen at higher dosages or with greater participant numbers though, as there 
appeared to be a trend toward a difference (p=0.081). A significant difference in this measure 
would likely not have affected our conclusions though, as an increase in urine (excreted) 
creatinine would be expected in a group supplementing with creatine. 
Both groups saw a significant increase in CrCl between baseline and 4 months, but this 
difference was not statistically significant at 8 and 12 months. The increase appeared greater in 
the creatine group, which suggests that at higher dosages this effect could become significant. 
This would be expected, as the increased creatine ingestion would cause an increase in creatinine 
excretion, assuming cellular saturation of creatine. It is also for this reason that increased 
creatinine clearance is not a health concern, as it points to increased excretion. In instances of 
chronic and acute kidney disease, creatinine clearance is reduced, and neither experimental group 
experienced this. Further research is required in this area to ascertain the effect(s) creatine 
supplementation may have on creatinine clearance. 
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Overall, there is little evidence to suggest creatine supplementation of this amount and time, 
within this population has any adverse effects on kidney health. Serum creatinine significantly 
decreased, urine creatinine was not statistically different, and creatinine clearance increased only 
significantly between baseline and 4 months before returning to normal. Even if all these 
measures did significantly increase, this would not be unexpected in a group supplementing with 
creatine, as its metabolism would cause an increase in the byproducts (creatinine) to be present. 
The decrease in serum creatinine suggest that neither group was able to maintain their creatinine 
levels and thus future research should likely experiment with higher creatine dosing protocols to 
ensure tissue saturation, although caution should be exercised when supplementing with creatine, 
especially in populations with potential renal complications or at higher dosages. Future research 
should explore these avenues to more accurately define safe and potentially unsafe 
supplementation dosages on renal function. 
Even though adverse effects of creatine supplementation on renal and liver function remain to be 
proven, creatinine (the byproduct of creatine) is primarily filtered and excreted by the kidneys. It 
will continue to be necessary to test and observe the effects creatine supplementation has on the 
renal system in the event that evidence of adverse reactions simply hasn’t been discovered yet.    
4.5.3 Creatine and Cramping 
Previous studies observing effects of creatine supplementation on muscle cramping have been 
inconsistent. A recent review (Kim et al., 2011) concluded there was insufficient evidence to 
support the theory that creatine supplementation causes an electrolyte imbalance and leads to 
muscular cramping. It has also been theorized that there is an increased hydration demand while 
supplementing with creatine, because creatine supplementation increases intracellular water, and 
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that this could contribute to muscular cramping, although there is no evidence to support this 
claim in the literature (Lopez et al., 2009). A review done in 2008 (Dalbo et al.) concluded that 
not only was there no reason to believe that creatine supplementation would increase the risk of 
dehydration or muscle cramps, but that creatine can increase total body water, lower core body 
temperature, and reduce exercise heart and sweat rate, thereby decreasing the risk of dehydration 
when exercising. Our results showed a 150% increased incidence of muscle cramping in those 
supplementing with creatine, so perhaps in certain populations (such as older adults) the 
hydration demand of creatine is greater, or perhaps the increased workload the participants 
supplementing with creatine were able to undertake contributed to cramping. Another study 
examining the effects of creatine supplementation and resistance training in older adults 
(Chrusch et al., 2001) found a significant increase in muscle cramping in participants 
supplementing with creatine. This result is in contradiction to other studies, which have found no 
significant incidence of muscle cramping with creatine supplementation (Dalbo et al., 2008, 
Greenwood et al., 2003, Vandenburgh et al., 1997). 
Other studies have shown significant increases in training volume/intensity with creatine 
supplementation (Candow et al., 2008) vs. placebo, indicating that creatine may allow 
participants to push harder in training, thus increasing their risk of cramps, pulls, and strains. 
Due to the mixed results and inconsistent reporting of these types of AEs, continued attention in 
future research will be necessary to determine the nature of the relationship between them and 
creatine supplementation. 
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4.5.4 Creatine and Gastrointestinal (GI) Distress 
In a similar fashion to muscle cramping incidents, reports of GI distress while supplementing 
with creatine are inconsistent. Some studies show an incidence rate for GI related issues in over 
30% of participants (Juhn et al., 1999; Vandenburgh et al., 1997), while others report no GI 
related disturbances at all (Kreider et al., 1998; Greenhaff et al., 1998). Several sources have 
postulated that GI distress observed in those supplementing with creatine is a result of the 
supplement not having completely dissolved before ingestion and that this problem could be 
avoided by either mixing the supplement in a more viscous medium (yogurt) and/or taking it in 
conjunction with a meal (Kim et al., 2011; Tarnopolsky, 2010). It should be noted that we 
heeded advice of the previous literature and instructed our participants to ingest their respective 
supplement with a meal on non-exercise days in an effort to minimize GI distress. The 
Tarnopolsky (2010) study cited a 5% incidence rate for GI disturbances while ours were 29% 
(GI) and 14% (cramping) in the creatine group vs. 11% (GI) and 6% (cramping) in the placebo 
group. These findings lend credibility to previously anecdotal claims of GI related disturbances 
occurring with creatine supplementation (Juhn et al., 1999; Lopez et al., 2009) and refute other 
research, which found no difference in GI symptom incidence between creatine and placebo 
groups (Groeneveld et al., 2005; Juhn et al., 1999; Vandenburgh et al., 1997). Interestingly, the 
Groenveld study showed an incidence of GI related symptoms as high as 35% (11% higher than 
the placebo group) but this difference was not found to be significant. Additional research must 
be performed to ascertain the nature of the relationship between creatine supplementation and 
these side effects, but in the meantime anyone planning to supplement with creatine should be 
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made aware of these possible side effects.  
4.6 Future Directions 
The present research indicates no serious risk to liver health at the tested dosage in the observed 
population. While it is also unlikely that creatine supplementation adversely affects kidney 
function, all our measurements of creatinine showed higher levels in the creatine vs. placebo 
groups, so renal involvement cannot be ignored and should continue to be assessed in future 
research, especially in populations that may be at increased risk for kidney disease. Future 
studies should experiment with higher dosages to ensure optimal creatine loading has occurred, 
as this was not evident in the current study. For example, serum creatinine was not maintained in 
either group over the course of the study. While this decrease was not significant in either group, 
it would be expected that optimal creatine loading would maintain or increase creatinine levels in 
the body. If this was not accomplished in the creatine group, then perhaps the dosage was not 
high enough to elicit other effects (positive or negative) within this population.  
 No significant differences were found in urine creatinine or creatinine clearance between the 
creatine and placebo groups either, although urine creatinine approached significance (p=0.081). 
A surplus of ingested creatine would be expected to increase renal elimination of creatinine 
(urine and creatinine clearance) in healthy individuals, or a buildup of creatinine in the blood or 
plasma (serum creatinine) in individuals with kidney dysfunction. Future studies performed at 
higher dosages could discover an optimal dosing protocol for this demographic and ascertain 
whether the dosage protocol in this study was insufficient to elicit results due to an absorption 
issue or muscle mass differences between young and older adults as has been suggested in 
previous research (Rawson et al., 2002). It is possible older adults require a higher standard 
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dosage of creatine to elicit physiological outcomes associated with creatine supplementation and 
determining the safety of supplementing at that level should be ascertained. 
Another potential contributing factor to the lack of statistical significance found in some of the 
measures is participant sample size. Graphs of serum creatinine, urine creatinine, and creatinine 
clearance did show trends for expected differences, but were found not to be statistically 
significant. A larger participant pool with the same absolute differences would increase statistical 
power, although the pool size would likely have to be 200-300 participants to see significant 
differences as mentioned earlier. 
While the need for additional long-term research in this population is needed, the present study 
indicates that for many of the outcome measures the largest differences from baseline were seen 
in the first 4-8 months. This suggests studies of 4-8 months would see the same or similar results 
with lower time commitment from both researchers and participants. More short-term studies (3-
6 months) will be valuable to this pool of research and should show changes in physiological 
outcomes of participants, especially at higher dosages. 
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Appendix A: Adverse Event Form 
	  
SUBJECT	  INITIALS:	  _______	   	   	   	   RECRUITMENT	  ID	  #:	  _________	  
	  	  
SERIOUS	  ADVERSE	  EVENT	  FORM	  	   	  *	  This	  will	  be	  reported	  to	  the	  Research	  Ethics	  Board	  	  
	  	  Describe	  the	  adverse	  event:	  ______________________________________________________	  __________________________________________________________________________________________________________________________________________________________	  _____________________________________________________________________________	  (Record	  diagnosis	  where	  available	  or	  describe	  event	  in	  as	  few	  words	  as	  possible.)	  	  	  	  1.	  Rate	  Intensity	  (severity):	  Please	  circle	  one	  
	  	  	  Mild	   	   	  Moderate	   	   Severe	  	   Life	  threatening	  	  	  2.	  Relationship	  to	  experimental	  procedure	  (supplement,	  exercise	  or	  other	  procedure):	  	  	  	   	  	  Not	  related	   	   Unlikely	   	   Possible	   	  	  	  	  	  Probable	   	  	  	  	  	  Definite	  	  	  	  	  Onset	  of	  Adverse	  Event	  (date/time):	  	   	   ____________________________	  Resolution	  of	  Adverse	  Event	  (date/time):	  	  ____________________________	  	  	   	  	  	  	  
Action	  Taken:	  ________________________________________________________________	  _____________________________________________________________________________	  _____________________________________________________________________________	  
_____________________________________________________________________________	  
_________________________________________________________________________________________________________
_________________________________________________________________________________________________________
_____________________	  	  	  	  Form	  completed	  by:	  _________________________	   Date:	  _______________________	  	  	  Signature	  of	  PI:_____________________________	   	  	   Date:________________________	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Appendix B: Liver Enzymes 
Alanine aminotransferase (ALT) - A very high level of ALT is frequently seen with acute 
hepatitis. Moderate increases may be seen with chronic hepatitis. People with blocked bile ducts, 
cirrhosis, and liver cancer may have ALT concentrations that are only moderately elevated or 
close to normal. 
Normal range 10-40 IU/L (5-45 U/L at local lab) 
Normal ranges vary by age, gender, and lab. 
Alkaline phosphatase (ALP) - ALP may be significantly increased with obstructed bile ducts, 
liver cancer, and also with bone disease. 
ALP in liver disease 
ALP results are usually evaluated along with other tests for liver disease. In some forms of liver 
disease, such as hepatitis, ALP is usually much less elevated than AST and ALT. When the bile 
ducts are blocked (usually by gallstones, scars from previous gallstones or surgery, or by 
cancers), ALP and bilirubin may be increased much more than AST or ALT. ALP may also be 
increased in liver cancer. 
ALP in bone disease 
In some bone diseases, such as Paget's disease, where bones become enlarged and deformed, or 
in certain cancers that spread to bone, ALP may be increased. 
If a person is being successfully treated for Paget's disease, then ALP levels will decrease or 
return to normal over time. If someone with bone or liver cancer responds to treatment, ALP 
levels should decrease. 
Moderately elevated ALP may result from other conditions, such as Hodgkin's 
lymphoma, congestive heart failure, ulcerative colitis, and certain bacterial infections. 
Low levels of ALP may be seen temporarily after blood transfusions or heart bypass surgery. A 
deficiency in zinc may cause decreased levels. A rare genetic disorder of bone metabolism called 
hypophosphatasia can cause severe, protracted low levels of ALP. Malnutrition or protein 
deficiency as well as Wilson disease could also be possible causes for lowered ALP. 
Normal Range 44-147 IU/L (30-110 U/L at local lab) 
Normal ranges vary by age, gender, and lab.  
Aspartate aminotransferase (AST) - A very high level of AST is frequently seen with acute 
hepatitis. AST may be normal to moderately increased with chronic hepatitis. In people with 
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blocked bile ducts, cirrhosis, and liver cancer, AST concentrations may be moderately increased 
or close to normal. When liver damage is due to alcohol, AST often increases much more than 
ALT (this is a pattern seen with few other liver diseases). AST is also increased after heart 
attacks and with muscle injury. 
Normal Range 10-34 IU/L (10-35 U/L at local lab)* normal ranges may vary among labs. 
Bilirubin - Bilirubin is increased in the blood when too much is being produced, less is being 
removed, due to bile duct obstructions, or to problems with bilirubin processing. It is not 
uncommon to see high bilirubin levels in newborns, typically 1 to 3 days old. 
Normal Range 0.3-1.9 mg/dL; equivalent to 5.1-32.5 umol/L (2-22 umol/L at local lab) 
Normal ranges vary by laboratory. 
References:  
Society for Biomedical Diabetes Research (SBDR) online; SI unit conversion calculator- 
http://www.soc-
bdr.org/rds/authors/unit_tables_conversions_and_genetic_dictionaries/conversion_in_si_units/i
ndex_en.html 
Medline Plus online - http://www.nlm.nih.gov/medlineplus/ency/article/003473.htm 
Medline Plus online - http://www.nlm.nih.gov/medlineplus/ency/article/003470.htm 
Medline Plus online - http://www.nlm.nih.gov/medlineplus/ency/article/003472.htm 
Medline Plus online - http://www.nlm.nih.gov/medlineplus/ency/article/003479.htm 
 
All references retrieved June 25, 2014. 
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Appendix C: Liver Test Procedure Sheets 
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Appendix D: Kidney Measures Information Sheet 
Serum Creatinine - The creatinine blood test is used along with a BUN (blood urea nitrogen) 
test to assess kidney function. Both are frequently ordered as part of a basic or comprehensive 
metabolic panel (BMP or CMP), groups of tests that are performed to evaluate the function of 
the body’s major organs. Serum creatinine measurements (along with your age, weight, and 
gender) also are used to calculate the estimated glomerular filtration rate (eGFR), which is used 
as a screening test to look for evidence of kidney damage.  
Increased creatinine levels in the blood suggest diseases or conditions that affect kidney function. 
Creatinine blood levels can also increase temporarily as a result of muscle injury and are 
generally slightly lower during pregnancy. Low blood levels of creatinine are not common, but 
they are also not usually a cause for concern. They can be seen with conditions that result in 
decreased muscle mass.  
Normal Range = 0.7-1.3 mg/dL (men) and 0.6-1.1 mg/dL (women); equivalent to 61.9-114.9 
umol/L and 53.0-97.2 umol/L respectively. Normal range for local lab = 45-110 umol/L 
Normal ranges are generally higher in men vs. women and vary among labs. 
Urine Creatinine - Levels of 24-hour urine creatinine are evaluated with blood levels as part of 
a creatinine clearance test. 
A combination of blood and urine creatinine levels may be used to calculate a creatinine 
clearance. This test measures how effectively the kidneys are filtering small molecules like 
creatinine out of the blood. 
Urine creatinine may also be used with a variety of other urine tests as a correction factor. Since 
it is produced and removed at a relatively constant rate, the amount of urine creatinine can be 
compared to the amount of another substance being measured. This stable excretion rate is useful 
when evaluating both 24-hour urine samples and random urine samples. Examples of this are 
when creatinine is measured with protein to calculate a urine protein/creatinine ratio 
(UP/CR) and when it is measured with microalbumin to calculate a microalbumin/creatinine 
ratio. 
The microalbumin/creatinine ratio is calculated to help determine how much albumin is escaping 
from the kidneys into the urine. People who have consistently detectable amounts of albumin in 
their urine (microalbuminuria) have an increased risk of developing progressive kidney 
failure and cardiovascular disease in the future. 
       
 
81 
 
Normal Range = 14-26 mg/kg (men) and 11-20 mg/kg (women); LOCAL LAB RANGE??? 
Normal ranges are generally higher in men vs. women and vary by lab. 
Creatinine Clearance - A creatinine clearance test is used to help evaluate the rate and 
efficiency of kidney filtration. It is used to help detect and diagnose kidney dysfunction and/or 
the presence of decreased blood flow to the kidneys. The creatinine clearance test may be 
ordered whenever a doctor wants to evaluate the filtration ability of the kidneys.  
Any disease or condition that affects the glomeruli can decrease the kidneys' ability to clear 
creatinine and other wastes out of the blood. When this occurs, the blood creatinine level will be 
increased and the creatinine clearance will be decreased because not as much creatinine is able to 
be excreted in the urine. 
A decreased creatinine clearance rate may also occur when there is decreased blood flow to the 
kidneys as may occur with congestive heart failure, obstruction within the kidney, or acute or 
chronic kidney failure. The less effective the kidney filtration, the greater the decrease in 
clearance. Increased creatinine clearance rates may occasionally be seen during pregnancy, 
exercise, and with diets high in meat, although this test is not typically used to monitor these 
conditions. 
Normal Range = 97-137 ml/min (men) and 88-128 ml/min (women). Normal range for local lab 
= 74-125 ml/min 
Normal ranges are generally higher in men vs. women and vary by lab. 
References: 
Lab Tests Online - http://labtestsonline.org/understanding/analytes/creatinine/tab/test/ 
Lab Tests Online - http://labtestsonline.org/understanding/analytes/creatinine-
clearance/tab/test/ 
Medline Plus online - http://www.nlm.nih.gov/medlineplus/ency/article/003610.htm 
Medline Plus online - http://www.nlm.nih.gov/medlineplus/ency/article/003611.htm 
Medline Plus online - http://www.nlm.nih.gov/medlineplus/ency/article/003475.htm 
Society for Biomedical Diabetes Research (SBDR) online; SI unit conversion calculator- 
http://www.soc-
bdr.org/rds/authors/unit_tables_conversions_and_genetic_dictionaries/conversion_in_si_units/i
ndex_en.html 
All references retrieved June 25, 2014. 
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Appendix E: Kidney Testing Reference Sheets 
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